EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Twist Bioscience's Enterprise Value is $1,577.7 Mil.
Twist Bioscience's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 was $-128.8 Mil. Therefore, Twist Bioscience's EV-to-FCF for today is -12.25.
The historical rank and industry rank for Twist Bioscience's EV-to-FCF or its related term are showing as below:
TWST'
s EV-to-FCF Range Over the Past 10 Years
Min: -57.17 Med: -8.01 Max: -1.8
Current: -12.25
During the past 8 years, the highest EV-to-FCF of Twist Bioscience was -1.80. The lowest was -57.17. And the median was -8.01.
TWST's EV-to-FCF is ranked worse than 100% of 103
companies
in the Medical Diagnostics & Research industry
Industry Median: 24.94
vs TWST: -12.25
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
The historical data trend for Twist Bioscience's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Twist Bioscience's EV-to-FCF
For the Diagnostics & Research subindustry, Twist Bioscience's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Twist Bioscience's EV-to-FCF Distribution in the Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Twist Bioscience's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Twist Bioscience's EV-to-FCF falls into.
Twist Bioscience's current Enterprise Value is $1,577.7 Mil.
Twist Bioscience's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-128.8 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Twist Bioscience (NAS:TWST) EV-to-FCF Explanation
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Twist Bioscience's PE Ratio for today is calculated as:
Twist Bioscience's share price for today is $31.54.
Twist Bioscience's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-3.610.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Twist Bioscience EV-to-FCF Related Terms
Thank you for viewing the detailed overview of Twist Bioscience's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.
Twist Bioscience (Twist Bioscience) Business Description
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well-plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies and powers cost-effective, rapid high-throughput synthesis, enabling researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of its revenue from the United States.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
TWST has been successfully added to your 